Skip to content
lifestyle.ketodash.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Sagimet Biosciences Inc.
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
September 2, 2026
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
August 25, 2026
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
August 13, 2026
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 11, 2026
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 4, 2026
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
May 20, 2026
Sagimet Biosciences Provides Strategic and Corporate Updates
May 20, 2026
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
April 20, 2026
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 6, 2026
1
2
Next Page
→